BullBD Old Apps Site
Home
Details Chart Today news Share news Top gainer Top Looser Upcoming events
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0 1 2 3 4 5 6 7 8 9 All
Bank Cement Ceramics Sector Corporate Bond Engineering Financial Institutions Food & Allied Fuel & Power IT Sector Insurance Jute Life Insurance Miscellaneous Mutual Funds Paper & Printing Pharmaceuticals & Chemicals Services & Real Estate Tannery Industries Telecommunication Textile Travel & Leisure All
  • Details
  • Chart
  • News

ORIONPHARM

All Eps Dividend Board Agm Q1 Q2 Q3

ORIONPHARM 28-Jan-2020

(Q2 Un-audited): Consolidated EPS was Tk. 0.97 for October-December 2019 as against Tk. 1.08 for October-December 2018; Consolidated EPS was Tk. 2.14 for July-December 2019 as against Tk. 2.06 for July-December 2018. Consolidated NOCFPS was Tk. 3.11 for July-December 2019 as against Tk. 4.98 for July-December 2018. (cont.)

ORIONPHARM 22-Jan-2020

As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on January 28, 2020 at 4:00 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended on December 31, 2019.

ORIONPHARM 03-Feb-2019

(Q2 Un-audited): Consolidated EPS was Tk. 1.08 for October-December, 2018 as against Tk. 0.97 for October-December, 2017; Consolidated EPS was Tk. 2.06 for July-December, 2018 as against Tk. 2.07 for July-December, 2017. Consolidated NOCFPS was Tk. 4.98 for July-December, 2018 as against Tk. 4.81 for July-December, 2017. (cont.)

ORIONPHARM 27-Jan-2019

As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on January 31, 2019 at 5:00 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended on December 31, 2018.

ORIONPHARM 29-Jan-2018

(Q2 Un-audited): Consolidated EPS was Tk. 0.97 for October-December, 2017 as against Tk. 1.29 for October-December, 2016; Consolidated EPS was Tk. 2.07 for July-December, 2017 as against Tk. 2.46 for July-December, 2016. Consolidated NOCFPS was Tk. 4.81 for July-December, 2017 as against Tk. 3.22 for July-December, 2016. (cont.)

ORIONPHARM 23-Jan-2018

As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on January 28, 2018 at 4:30 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended on December 31, 2017.

ORIONPHARM 01-Feb-2017

(Q2 Un-audited): Consolidated EPS was Tk. 1.29 for October-December, 2016 as against Tk. 1.27 for October-December, 2015; Consolidated EPS was Tk. 2.46 for July-December, 2016 as against Tk. 2.00 for July-December, 2015. Consolidated NOCFPS was Tk. 3.22 for July-December, 2016 as against Tk. 4.71 for July-December, 2015. (cont.)

ORIONPHARM 24-Jan-2017

As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on January 31, 2017 at 5:00 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended on December 31, 2016.

ORIONPHARM 30-Jul-2015

(Continuation news of ORIONPHARM-Q2): Consolidated NAV per share including revaluation surplus was Tk. 68.31 as of June 30, 2015 and Tk. 67.50 as of December 31, 2014, NAV per share excluding revaluation surplus was Tk. 61.68 as of June 30, 2015 and Tk. 58.25 as of December 31, 2014.(end)

ORIONPHARM 30-Jul-2015

(Q2 Un-audited): Consolidated EPS for April-June, 2015 was Tk. 0.74 as against Tk. 1.40 for April-June, 2014, Consolidated EPS for Jan-June, 2015 was Tk. 2.15 as against Tk. 3.03 for Jan-June, 2014. Consolidated NOCFPS was Tk. 4.32 for Jan-June, 2015 as against Tk. 6.81 for Jan-June, 2014. (cont.)

Previous Next page